Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TSHR | P16473 | 1/20 | 0.50 |
| ▸ | CA1 | P00915 | 4/20 | 0.47 |
| ▸ | CA2 | P00918 | 2/20 | 0.47 |
| ▸ | CA7 | P43166 | 2/20 | 0.47 |
| ▸ | CA9 | Q16790 | 2/20 | 0.47 |
| ▸ | TACR1 | P25103 | 3/20 | 0.46 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.45 |
| ▸ | MEN1 | O00255 | 1/20 | 0.44 |
| ▸ | TAAR1 | Q96RJ0 | 1/20 | 0.44 |
| ▸ | HTT | P42858 | 1/20 | 0.44 |
| ▸ | SLC1A1 | P43005 | 1/20 | 0.44 |
| ▸ | CTSB | P07858 | 1/20 | 0.42 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL121000 | 1.00 | TSHR (0.50) | TSHRCA1CA2CA7CA9 | |
| SCHEMBL7627184 | 1.00 | TSHR (0.50) | TSHRCA1CA2CA7CA9 | |
| SCHEMBL27694646 | 0.84 | TSHR (0.48) | TSHRCA1CA2CA7CA9 | |
| SCHEMBL22332007 | 0.82 | KMT2A (0.48) | TSHRCA1CA2CA7CA9 | |
| SCHEMBL27604046 | 0.82 | TSHR (0.47) | TSHRKMT2AMEN1TAAR1HTT | |
| SCHEMBL8030875 | 0.81 | CA1 (0.51) | TSHRCA1CA2CA7CA9 | |
| SCHEMBL13418948 | 0.81 | TSHR (0.54) | TSHRCA1CA2CA7CA9 | |
| SCHEMBL7190391 | 0.81 | CA1 (0.54) | TSHRCA1CA2HTT | |
| SCHEMBL3557233 | 0.81 | CA1 (0.54) | TSHRCA1CA2HTT | |
| SCHEMBL5229745 | 0.81 | CA1 (0.54) | TSHRCA1CA2HTT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20130196987-A1 | MACROCYCLIC COMPOUNDS USEFUL AS PHARMACEUTICALS | EISAI CO., LTD. (JP) | 2013-08-01 | — | — | US | disclosed |
| US-8329742-B2 | Macrocyclic compounds useful as pharmaceuticals | EISAI CO., LTD. (JP) | 2012-12-11 | — | — | US | disclosed |
| US-20110144101-A1 | MACROCYCLIC COMPOUNDS USEFUL AS PHARMACEUTICALS | EISAI CO., LTD. (JP) | 2011-06-16 | — | — | US | disclosed |
| EP-1368334-B1 | PROCESS FOR PREPARING INTERMEDIATES FOR THE MANUFACTURE OF DISCODERMOLIDE AND DISCODERMOLIDE ANALOGUES | NOVARTIS AG (CH) | 2007-09-05 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110144101-A1 | MACROCYCLIC COMPOUNDS USEFUL AS PHARMACEUTICALS | FLT1, TBXA2R, VEGFA | TSHR 213/4885CA1 3596/4885CA2 3153/4885 |
| US-20130196987-A1 | MACROCYCLIC COMPOUNDS USEFUL AS PHARMACEUTICALS | FLT4, VEGFA, FLT1 | TSHR 1244/4885CA1 3237/4885CA2 2388/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.